The first serious adverse event (SAE) comprising a complex renal cyst developing during crizotinib treatment was reported in a phase II study of crizotinib 250 mg twice daily in patients with ALK-positive NSCLC (PROFILE 1005) in January 2011 (patient 1, Table 1). This evidence concerns the gene ALK and non-small cell lung carcinoma.